Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2021-08-03 eCollection Date: 2021-12-01 DOI:10.2217/hep-2020-0034

Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi

{"title":"Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma.","authors":"Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi","doi":"10.2217/hep-2020-0034","DOIUrl":null,"url":null,"abstract":"<p><p>While researchers know that tumor mutational burden (TMB) is low in hepatocellular carcinoma (HCC), prior studies have not investigated TMB in cirrhosis, small early HCC and progressed HCC. HCC (n = 18) and cirrhosis (n = 6) cases were identified. TMB was determined by a 1.7 megabase, 409-gene next-generation sequencing panel. TMB values were defined as the number of nonsynonymous variants per megabase of sequence. There was no significant difference between cirrhosis versus small early HCC or between cohorts when stratified by size, early versus progressed, differentiation or morphology. There was a significant difference between cirrhosis and small early HCC versus progressed HCC (p = 0.045), suggesting TMB may be related to HCC progression. TMB similarities in small early HCC and background cirrhosis suggest TMB is not a useful tool for diagnosing small early HCC. Additional study is needed to address TMB in histological and molecular subsets of HCC.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2021-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/fb/hep-08-39.PMC8577511.pdf","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2020-0034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 8

Abstract

While researchers know that tumor mutational burden (TMB) is low in hepatocellular carcinoma (HCC), prior studies have not investigated TMB in cirrhosis, small early HCC and progressed HCC. HCC (n = 18) and cirrhosis (n = 6) cases were identified. TMB was determined by a 1.7 megabase, 409-gene next-generation sequencing panel. TMB values were defined as the number of nonsynonymous variants per megabase of sequence. There was no significant difference between cirrhosis versus small early HCC or between cohorts when stratified by size, early versus progressed, differentiation or morphology. There was a significant difference between cirrhosis and small early HCC versus progressed HCC (p = 0.045), suggesting TMB may be related to HCC progression. TMB similarities in small early HCC and background cirrhosis suggest TMB is not a useful tool for diagnosing small early HCC. Additional study is needed to address TMB in histological and molecular subsets of HCC.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

早期小肝癌和进展性肝癌肿瘤突变负荷的评价。

虽然研究人员知道肝细胞癌(HCC)的肿瘤突变负担(tumor mutational burden, TMB)较低，但之前的研究尚未对肝硬化、早期小肝癌和进展期肝癌的TMB进行研究。肝细胞癌(18例)和肝硬化(6例)。TMB由1.7兆碱基、409个基因的下一代测序面板确定。TMB值被定义为每兆碱基序列的非同义变体的数量。肝硬化与小的早期HCC之间，或按大小、早期与进展、分化或形态分层的队列之间，没有显著差异。肝硬化、小早期HCC与进展性HCC的差异有统计学意义(p = 0.045)，提示TMB可能与HCC进展有关。TMB在早期小肝癌和背景肝硬化中的相似性提示TMB不是诊断早期小肝癌的有用工具。需要进一步研究TMB在HCC的组织学和分子亚群中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.